Current Clinical Trials
Find a Clinical Trial
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."
| Therapeutic Area | Condition | Study Number |
Description | Status (click on link to learn more) |
|---|---|---|---|---|
| Haematology & Thrombosis |
Hemophilia A | OPERA | Register of Patients With haEmophilia A tReated With Afstyla® (OPERA) | Active, Not Recruiting |
| Hemophilia B | OrPHEe | Observatory of Patients With Haemophilia B Treated by IdElvion® | Recruiting | |
| Hemophilia B | CSL220_1002 | Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B | Active, Not Recruiting | |
| Hemophilia B | CSL222_3001 | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients |
Active, Not Recruiting | |
| Sickle Cell | CSL889_1001 | A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients with Sickle Cell Disease |
Recruiting |
|
| Von Willebrand Disease |
OPALE | Registry of Patients With Von WilLEbrand Disease Treated With Voncento® (OPALE) |
Active, Not Recruiting |
|
| Cardiovascular and Metabolic | Acute Coronary Syndrome | CSL112_3001 | Study to investigateCSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) | Recruiting |
| End Stage Kidney Disease | CSL300_2301 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Not Yet Recruiting | |
| Diabetic Kidney Disease | CSL346_2001 | A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal AntibodyCSL346in Subjects With Diabetic Kidney Disease | Recruiting | |
| Immunology and Neurology | Dermatomyositis (DM) | IgPro20_3007 | A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) [RECLAIIM] | Recruiting |
| Pediatric CIDP | IgPro10_4002 | Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | Recruiting | |
| Hereditary Angioedema (HAE) |
CSL312_3002 | Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks | Active, Not Recruiting | |
| Hidradenitis Suppurativa and Palmoplantar Pustulosis | CSL324_1002 | A study of the safety and pharmacokinetics of repeat doses ofCSL324in subjects with hidradenitis suppurativa and palmoplantar pustulosis | Active, Not Recruiting | |
| Inflammatory Neuropathy | pHeNIx |
Hizentra® in Inflammatory Neuropathies - pHeNIx Study | Recruiting | |
| Healthy Subjects | CSL312_1004 | A Phase 1 Study to Compare the Pharmacokinetic Properties of CSL312 Administered by Subcutaneous Prefilled Syringe Assembled to Autoinjector to Prefilled Syringe Assembled to Needle Safety Device in Healthy Adult Subjects |
Recruiting | |
| Healthy Subjects | CSL730_1002 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SubcutaneousCSL730in Healthy Adult Subjects | Recruiting | |
| Respiratory | Mild Asthma | CSL311_1001 | A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. | Recruiting |
| Idiopathic Pulmonary Fibrosis | CSL312_2002 | CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis | Recruiting | |
| Non-cystic Fibrosis Bronchiectasis (NCFB) |
CSL787_1001 | Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) | Recruiting | |
| alpha-1 antitrypsin deficiency |
AmAREtTI Study |
Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage) |
Recruiting |
|
| Transplant | Antibody-mediated kidney transplant rejection | CSL300_3001 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients [IMAGINE] | Recruiting |
| Acute GVHD (aGVHD) | CSL964_2001 | The Safety and Efficacy of Alpha 1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant [MODULATE] | Recruiting | |
| Graft Versus Host Disease (GVHD) | CSL964_5001 | A study on theefficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD | Recruiting | |
| Chronic Active Antibody Mediated Rejection | AMR BoD | Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection |
Recruiting | |
|
COMPLETED STUDIES: |
||||
| COVID-19 | COVID-19 | CSL312_COVID-19 | A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) | Results |
| COVID-19 | CSL324_COVID-19 | CSL324 in COVID‑19 | Withdrawn | |
| COVID-19 | CSL760_1001 | Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects | Cancelled | |
| Haematology & Thrombosis |
Reversal of acquired coagulation factor deficiency | BE1116_4001 |
An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra®or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding |
Completed |
| Congenital Fibrinogen Deficiency | BI3023_4003 | An Observational Study of the Safety and Efficacy of Fibrinogen Concentrate Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | Completed | |
| Hemophilia A |
CSL627_3001 | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A |
Results | |
| Hemophilia B | CSL222_2001 | Dose Confirmation Trial of AAV5-hFIXco-Padua |
Results |
|
| Hemophilia B | CSL654_3001 | A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B |
Results | |
| Hemophilia B | CSL654_3002 | A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B |
Results | |
| Hemophilia B | CSL654_3003 | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B |
Results |
|
| Hemophilia B | CT-AMT-060-01 | Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B |
Results | |
| Hemophilia A or B | CSL689_2001 | Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors | Cancelled | |
| PICC-associated Thrombosis |
CSL312_1002 |
A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line | Withdrawn |
|
| Sickle Cell | CSL200_1001 | CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease |
Cancelled |
|
| Von Willebrand Disease | CSLCT-BIO-12-83 | Study of Voncento®in Subjects With Von Willebrand Disease | Completed | |
| Cardiovascular and Metabolic | Coronary Heart Disease | CSL112_1001 | Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults | Completed |
| Renal Impairment and Acute Myocardial Infarction | CSL112_2001 | A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction | Results | |
| Acute Myocardial Infarction | CSLCT-HDL-12-77 |
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction. |
Results |
|
| Immunology and Neurology |
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro20_3004 |
Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Results |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
IgPro10_5004 |
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) |
Cancelled |
|
| Hereditary Angioedema (HAE) | CSL312_2001 |
A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) |
Completed |
|
| Hereditary Angioedema (HAE) |
CSL312_3001 | CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks |
Completed | |
| Hereditary Angioedema (HAE) |
CSL830_2001 | A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route |
Results | |
| Hereditary Angioedema (HAE) |
CSL830_3001 | A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema |
Results | |
| Hereditary Angioedema (HAE) | CSL830_3002 | A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema | Results | |
| Hereditary Angioedema (HAE) |
CSL830_3003 |
A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects |
Results |
|
| HIV-1 | CAL-USA-11 | An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART | Results | |
| Primary Immune Deficiency (PID) | IgPro20_1001 | Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | Results | |
| Primary Immune Deficiency (PID) | IgPro20_4004 | Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) | Results | |
| Primary Immune Deficiency(PID) | IgPro20_4005 | Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (Hizentra®) on Weekly and Biweekly Schedules | Results | |
| Systemic Sclerosis | IgPro10_2001 | Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis | Withdrawn | |
| Systemic Sclerosis | IgPro20_2001 | A study to investigate the safety, tolerability, and pharmacokinetics ofIgPro20in subjects with diffuse cutaneous systemic sclerosis (dcSSc) |
Completed |
|
| Healthy Subjects | CSL312_1003 | A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults | Completed |
|
| Healthy Subjects | CSL324_1001 | Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults | Completed | |
| Healthy Subjects | CSL324_1003 | Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects |
Completed | |
| Healthy Subjects | CSL730_1001 | Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults |
Cancelled |
|
| Transplant | Antibody-mediated kidney transplant rejection | CSL842_3001 | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR)in Adult Renal Transplant Recipients | Cancelled |